Bluebird’s Susanna High Jumps to Dyne for Chief Operating Officer Role

Xconomy Boston — 

Dyne Therapeutics has appointed Susanna High to serve as its chief operating officer, the same position she held most recently at Bluebird Bio (NASDAQ: BLUE). High’s experience also includes senior roles at Alynlam Pharmaceuticals (NASDAQ: ALNY) and Millennium Pharmaceuticals. Last year, Cambridge, MA-based Dyne raised $50 million in Series A financing to support the development of drugs for rare muscular disorders.